{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:47:04Z","timestamp":1792860424451,"version":"4.5.0"},"reference-count":212,"publisher":"Japan Atherosclerosis Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2021,9,1]]},"DOI":"10.5551\/jat.rv17054","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T22:06:45Z","timestamp":1620857205000},"page":"883-904","source":"Crossref","is-referenced-by-count":41,"title":["Current Diagnosis and Management of Primary Chylomicronemia"],"prefix":"10.5551","volume":"28","author":[{"given":"Hiroaki","family":"Okazaki","sequence":"first","affiliation":[{"name":"Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanari","family":"Gotoda","sequence":"additional","affiliation":[{"name":"Department of Metabolic Biochemistry, Faculty of Medicine, Kyorin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsune","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[{"name":"Faculty of Health Science, Juntendo University, Juntendo University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Hayashi","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Research Institute of Environmental Medicine, Nagoya University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Health Care Center, Rinku Innovation Center for Wellness Care and Activities (RICWA), Rinku General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Institute for Biological Functions, Chubu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","unstructured":"1) Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, apoC-II deficiency, and hepatic lipase deficiency. The metabolic and molecular bases of inherited disease, 2001; 2: 2789-2816"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, Bujo H, Ishibashi S, Arai H, Yamashita S, Harada-Shiba M, Eto M, Hayashi T, Sone H, Suzuki H, Yamada N, Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in Japan. Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb, 2012; 19: 1-12","DOI":"10.5551\/jat.10702"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Bor\u00e9n J, Bruckert E, Catapano AL, Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AFH, Stroes E, Taskinen M-RR, Tybj\u00e6rg-Hansen A, Watts GF, Wiklund O, Panel EASC. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol, 2014; 2: 655-666","DOI":"10.1016\/S2213-8587(13)70191-8"},{"key":"4","unstructured":"4) Burnett JR, Hooper AJ, Hegele RA. Familial Lipoprotein Lipase Deficiency [Internet]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A, editors. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle; 1993 [cited 2019 Oct 28]. Available from: http: \/\/www.ncbi.nlm.nih.gov\/books\/NBK1308\/"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol, 2015; 11: 352-362","DOI":"10.1038\/nrendo.2015.26"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kihara S, Matsuzawa Y, Kubo M, Nozaki S, Funahashi T, Yamashita S, Sho N, Tarui S. Autoimmune hyperchylomicronemia. N Engl J Med, 1989; 320: 1255-1259","DOI":"10.1056\/NEJM198905113201906"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, Khovidhunkit W, Dufour R, Garg A, McMahon MA, Pullinger CR, Sandoval NP, Hu X, Allan CM, Larsson M, Machida T, Murakami M, Reue K, Tontonoz P, Goldberg IJ, Moulin P, Charri\u00e8re S, Fong LG, Nakajima K, Young SG. Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia. N Engl J Med, 2017; 376: 1647-1658","DOI":"10.1056\/NEJMoa1611930"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Inoue M, Kawamura M, Yamamoto H, Takahashi T, Kihara S. Juvenile-onset systemic lupus erythematosus with severe hypertriglyceridemia induced by anti-apolipoprotein C-II antibody. Pediatr Int, 2019; 61: 201-203","DOI":"10.1111\/ped.13736"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Miyashita K, Lutz J, Hudgins LC, Toib D, Ashraf AP, Song W, Murakami M, Nakajima K, Ploug M, Fong LG, Young SG, Beigneux AP. Chylomicronemia from GPIHBP1 autoantibodies. J Lipid Res, 2020; 61: 1365-1376","DOI":"10.1194\/jlr.R120001116"},{"key":"10","unstructured":"10) Havel RJ. Pathogenesis, differentiation and management of hypertriglyceridemia. Adv Intern Med, 1969; 15: 117-154"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Navina S, Acharya C, DeLany JP, Orlichenko LS, Baty CJ, Shiva SS, Durgampudi C, Karlsson JM, Lee K, Bae KT, Furlan A, Behari J, Liu S, McHale T, Nichols L, Papachristou GI, Yadav D, Singh VP. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med, 2011; 3: 107ra110","DOI":"10.1126\/scitranslmed.3002573"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Valdivielso P, Ram\u00edrez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med, 2014; 25: 689-694","DOI":"10.1016\/j.ejim.2014.08.008"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AFH, Endocrine society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2012; 97: 2969-2989","DOI":"10.1210\/jc.2011-3213"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Rawla P, Sunkara T, Thandra KC, Gaduputi V. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. Clin J Gastroenterol, 2018; 11: 441-448","DOI":"10.1007\/s12328-018-0881-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Hegele RA, Berberich AJ, Ban MR, Wang J, Digenio A, Alexander VJ, D\u2019Erasmo L, Arca M, Jones A, Bruckert E, Stroes ES, Bergeron J, Civeira F, Witztum JL, Gaudet D. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. Journal of Clinical Lipidology, 2018; 12: 920-927.e4","DOI":"10.1016\/j.jacl.2018.03.093"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the Genomic Era: A New Paradigm. Endocrine Reviews, 2015; 36: 131-147","DOI":"10.1210\/er.2014-1062"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Brown WV, Goldberg IJ, Young SG. JCL Roundtable: Hypertriglyceridemia due to defects in lipoprotein lipase function. J Clin Lipidol, 2015; 9: 274-280","DOI":"10.1016\/j.jacl.2015.03.009"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Murase T, Okubo M, Ebara T, Mori Y. Severe hypertriglyceridemia in Japan: Differences in causes and therapeutic responses. J Clin Lipidol, 2017; 11: 1383-1392","DOI":"10.1016\/j.jacl.2017.08.006"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Surendran RP, Visser ME, Heemelaar S, Wang J, Peter J, Defesche JC, Kuivenhoven JA, Hosseini M, P\u00e9terfy M, Kastelein JJP, Johansen CT, Hegele RA, Stroes ESG, Dallinga-Thie GM. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med, 2012; 272: 185-196","DOI":"10.1111\/j.1365-2796.2012.02516.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Rabacchi C, Pisciotta L, Cefal\u00f9 AB, Noto D, Fresa R, Tarugi P, Averna M, Bertolini S, Calandra S. Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia. Atherosclerosis, 2015; 241: 79-86","DOI":"10.1016\/j.atherosclerosis.2015.04.815"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Chokshi N, Blumenschein SD, Ahmad Z, Garg A. Genotype-phenotype relationships in patients with type I hyperlipoproteinemia. J Clin Lipidol, 2014; 8: 287-295","DOI":"10.1016\/j.jacl.2014.02.006"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Rodrigues R, Artieda M, Tejedor D, Mart\u00ednez A, Konstantinova P, Petry H, Meyer C, Corzo D, Sundgreen C, Klor HU, Gouni-Berthold I, Westphal S, Steinhagen-Thiessen E, Julius U, Winkler K, Stroes E, Vogt A, Hardt P, Prophet H, Otte B, Nordestgaard BG, Deeb SS, Brunzell JD. Pathogenic classification of LPL gene variants reported to be associated with LPL deficiency. J Clin Lipidol, 2016; 10: 394-409","DOI":"10.1016\/j.jacl.2015.12.015"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Nilsson-Ehle P, Schotz MC. A stable, radioactive substrate emulsion for assay of lipoprotein lipase. J Lipid Res, 1976; 17: 536-541","DOI":"10.1016\/S0022-2275(20)41752-3"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) P\u00e9terfy M, Ben-Zeev O, Mao HZ, Weissglas-Volkov D, Aouizerat BE, Pullinger CR, Frost PH, Kane JP, Malloy MJ, Reue K, Pajukanta P, Doolittle MH. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nat Genet, 2007; 39: 1483-1487","DOI":"10.1038\/ng.2007.24"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Cefal\u00f9 AB, Noto D, Arpi ML, Yin F, Spina R, Hilden H, Barbagallo CM, Carroccio A, Tarugi P, Squatrito S, Vigneri R, Taskinen M-R, P\u00e9terfy M, Averna MR. Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. J Clin Endocrinol Metab, 2009; 94: 4584-4590","DOI":"10.1210\/jc.2009-0594"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) P\u00e9terfy M, Bedoya C, Giacobbe C, Pagano C, Gentile M, Rubba P, Fortunato G, Di Taranto MD. Characterization of two novel pathogenic variants at compound heterozygous status in lipase maturation factor 1 gene causing severe hypertriglyceridemia. J Clin Lipidol, 2018; 12: 1253-1259","DOI":"10.1016\/j.jacl.2018.07.008"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Serveaux Dancer M, Di Filippo M, Marmontel O, Val\u00e9ro R, Piombo Rivarola MDC, Peretti N, Caussy C, Krempf M, Verg\u00e8s B, Mahl M, Mar\u00e7ais C, Moulin P, Charri\u00e8re S. New rare genetic variants of LMF1 gene identified in severe hypertriglyceridemia. J Clin Lipidol, 2018; 12: 1244-1252","DOI":"10.1016\/j.jacl.2018.06.018"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Liu Y, Xu J, Tao W, Yu R, Zhang X. A Compound Heterozygous Mutation of Lipase Maturation Factor 1 is Responsible for Hypertriglyceridemia of a Patient. J Atheroscler Thromb, 2019; 26: 136-144","DOI":"10.5551\/jat.44537"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Chen W-W, Yang Q, Li X-Y, Shi X-L, Pu N, Lu G-T, Tong Z-H, Chen J-M, Li W-Q. Identification of a novel and heterozygous LMF1 nonsense mutation in an acute pancreatitis patient with severe hypertriglyceridemia, severe obesity and heavy smoking. Lipids Health Dis, 2019; 18: 68","DOI":"10.1186\/s12944-019-1012-9"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ioka RX, Kang M-J, Kamiyama S, Kim D-H, Magoori K, Kamataki A, Ito Y, Takei YA, Sasaki M, Suzuki T, Sasano H, Takahashi S, Sakai J, Fujino T, Yamamoto TT. Expression cloning and characterization of a novel glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein, GPI-HBP1. J Biol Chem, 2003; 278: 7344-7349","DOI":"10.1074\/jbc.M211932200"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Beigneux AP, Davies BSJ, Gin P, Weinstein MM, Farber E, Qiao X, Peale F, Bunting S, Walzem RL, Wong JS, Blaner WS, Ding Z-M, Melford K, Wongsiriroj N, Shu X, de Sauvage F, Ryan RO, Fong LG, Bensadoun A, Young SG. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab, 2007; 5: 279-291","DOI":"10.1016\/j.cmet.2007.02.002"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Rios JJ, Shastry S, Jasso J, Hauser N, Garg A, Bensadoun A, Cohen JC, Hobbs HH. Deletion of GPIHBP1 causing severe chylomicronemia. J Inherit Metab Dis, 2012; 35: 531-540","DOI":"10.1007\/s10545-011-9406-5"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Adeyo O, Goulbourne CN, Bensadoun A, Beigneux AP, Fong LG, Young SG. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 and the intravascular processing of triglyceride-rich lipoproteins. J Intern Med, 2012; 272: 528-540","DOI":"10.1111\/joim.12003"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Patni N, Brothers J, Xing C, Garg A. Type 1 hyperlipoproteinemia in a child with large homozygous deletion encompassing GPIHBP1. J Clin Lipidol, 2016; 10: 1035-1039.e2","DOI":"10.1016\/j.jacl.2016.04.001"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Rabacchi C, D\u2019Addato S, Palmisano S, Lucchi T, Bertolini S, Calandra S, Tarugi P. Clinical and genetic features of 3 patients with familial chylomicronemia due to mutations in GPIHBP1 gene. J Clin Lipidol, 2016; 10: 915-921.e4","DOI":"10.1016\/j.jacl.2016.03.009"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Chyzhyk V, Kozmic S, Brown AS, Hudgins LC, Starc TJ, Davila AD, Blevins TC, Diffenderfer MR, He L, Geller AS, Rush C, Hegele RA, Schaefer EJ. Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence. J Clin Lipidol, 2019; 13: 89-99","DOI":"10.1016\/j.jacl.2018.09.007"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Franssen R, Young SG, Peelman F, Hertecant J, Sierts JA, Schimmel AWM, Bensadoun A, Kastelein JJP, Fong LG, Dallinga-Thie GM, Beigneux AP. Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet, 2010; 3: 169-178","DOI":"10.1161\/CIRCGENETICS.109.908905"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Breckenridge WC, Little JA, Steiner G, Chow A, Poapst M. Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med, 1978; 298: 1265-1273","DOI":"10.1056\/NEJM197806082982301"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Yamamura T, Sudo H, Ishikawa K, Yamamoto A. Familial type I hyperlipoproteinemia caused by apolipoprotein C-II deficiency. Atherosclerosis, 1979; 34: 53-65","DOI":"10.1016\/0021-9150(79)90106-0"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Okubo M, Toromanovic A, Ebara T, Murase T. Apolipoprotein C-II Tuzla: a novel large deletion in APOC2 caused by Alu-Alu homologous recombination in an infant with apolipoprotein C-II deficiency. Clin Chim Acta, 2015; 438: 148-153","DOI":"10.1016\/j.cca.2014.08.022"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Wolska A, Dunbar RL, Freeman LA, Ueda M, Amar MJ, Sviridov DO, Remaley AT. Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis, 2017; 267: 49-60","DOI":"10.1016\/j.atherosclerosis.2017.10.025"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Fojo SS, Beisiegel U, Beil U, Higuchi K, Bojanovski M, Gregg RE, Greten H, Brewer HB. Donor splice site mutation in the apolipoprotein (Apo) C-II gene (Apo C-IIHamburg) of a patient with Apo C-II deficiency. J Clin Invest, 1988; 82: 1489-1494","DOI":"10.1172\/JCI113756"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Streicher R, Geisel J, Weisshaar C, Avci H, Oette K, M\u00fcller-Wieland D, Krone W. A single nucleotide substitution in the promoter region of the apolipoprotein C-II gene identified in individuals with chylomicronemia. J Lipid Res, 1996; 37: 2599-2607","DOI":"10.1016\/S0022-2275(20)37463-0"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Okubo M, Hasegawa Y, Aoyama Y, Murase T. A G+1 to C mutation in a donor splice site of intron 2 in the apolipoprotein (apo) C-II gene in a patient with apo C-II deficiency. A possible interaction between apo C-II deficiency and apo E4 in a severely hypertriglyceridemic patient. Atherosclerosis, 1997; 130: 153-160","DOI":"10.1016\/S0021-9150(96)06061-3"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Takase S, Osuga J, Fujita H, Hara K, Sekiya M, Igarashi M, Takanashi M, Takeuchi Y, Izumida Y, Ohta K, Kumagai M, Nishi M, Kubota M, Masuda Y, Taira Y, Okazaki S, Iizuka Y, Yahagi N, Ohashi K, Yoshida H, Yanai H, Tada N, Gotoda T, Ishibashi S, Kadowaki T, Okazaki H. Apolipoprotein C-II deficiency with no rare variant in the APOC2 gene. J Atheroscler Thromb, 2013; 20: 481-493","DOI":"10.5551\/jat.16592"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science, 2001; 294: 169-173","DOI":"10.1126\/science.1064852"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, Chamuleau RA. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem, 2001; 276: 44512-44520","DOI":"10.1074\/jbc.M106888200"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem, 2005; 280: 21553-21560","DOI":"10.1074\/jbc.M411412200"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Merkel M, Heeren J. Give me A5 for lipoprotein hydrolysis! J Clin Invest, 2005; 115: 2694-2696","DOI":"10.1172\/JCI26712"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Mar\u00e7ais C, Verges B, Charri\u00e8re S, Pruneta V, Merlin M, Billon S, Perrot L, Drai J, Sassolas A, Pennacchio LA, Fruchart-Najib J, Fruchart J-C, Durlach V, Moulin P. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest, 2005; 115: 2862-2869","DOI":"10.1172\/JCI24471"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Priore Oliva C, Pisciotta L, Li Volti G, Sambataro MP, Cantafora A, Bellocchio A, Catapano A, Tarugi P, Bertolini S, Calandra S. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol, 2005; 25: 411-417","DOI":"10.1161\/01.ATV.0000153087.36428.dd"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Albers K, Schlein C, Wenner K, Lohse P, Bartelt A, Heeren J, Santer R, Merkel M. Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant. Atherosclerosis, 2014; 233: 97-103","DOI":"10.1016\/j.atherosclerosis.2013.12.009"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) D\u2019Erasmo L, Di Costanzo A, Cassandra F, Minicocci I, Polito L, Montali A, Ceci F, Arca M. Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes. Arterioscler Thromb Vasc Biol, 2019; 39: 2531-2541","DOI":"10.1161\/ATVBAHA.119.313401"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Okazaki H, Goldstein JL, Brown MS, Liang G. LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. J Biol Chem, 2010; 285: 6801-6810","DOI":"10.1074\/jbc.M109.079459"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Takanashi M, Kimura T, Li C, Tanaka M, Matsuhashi A, Yoshida H, Noda A, Xu P, Takase S, Okazaki S, Iizuka Y, Kumagai H, Ikeda Y, Gotoda T, Takahashi M, Yagyu H, Ishibashi S, Yamauchi T, Kadowaki T, Liang G, Okazaki H. Critical Role of SREBP-1c Large-VLDL Pathway in Environment-Induced Hypertriglyceridemia of Apo AV Deficiency. Arterioscler Thromb Vasc Biol, 2019; 39: 373-386","DOI":"10.1161\/ATVBAHA.118.311931"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ, 2007; 176: 1113-1120","DOI":"10.1503\/cmaj.060963"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Stefanutti C, Di Giacomo S, Vivenzio A, Labbadia G, Mazza F, D\u2019Alessandri G, Russi G, De Silvestro G, Marson P. Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study. Artif Organs, 2009; 33: 1096-1102","DOI":"10.1111\/j.1525-1594.2009.00810.x"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011; 123: 2292-2333","DOI":"10.1161\/CIR.0b013e3182160726"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Click B, Ketchum AM, Turner R, Whitcomb DC, Papachristou GI, Yadav D. The role of apheresis in hypertriglyceridemia-induced acute pancreatitis: A systematic review. Pancreatology, 2015; 15: 313-320","DOI":"10.1016\/j.pan.2015.02.010"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Inayat F, Zafar F, Riaz I, Younus F, Baig AS, Imran Z. Hypertriglyceridemic Pancreatitis: Is Insulin Monotherapy A Feasible Therapeutic Option? Cureus, 2018; 10: e3461","DOI":"10.7759\/cureus.3461"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FK, American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation, 2019; 140: e673-e691","DOI":"10.1161\/CIR.0000000000000709"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Greenberg BH. Primary Type V Hyperlipoproteinemia: A Descriptive Study in 32 Families. Ann Intern Med, 1977; 87: 526-534","DOI":"10.7326\/0003-4819-87-5-526"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Tada H, Kawashiri M-A, Nakahashi T, Yagi K, Chujo D, Ohbatake A, Mori Y, Mori S, Kometani M, Fujii H, Nohara A, Inazu A, Mabuchi H, Yamagishi M, Hayashi K. Clinical characteristics of Japanese patients with severe hypertriglyceridemia. J Clin Lipidol, 2015; 9: 519-524","DOI":"10.1016\/j.jacl.2015.05.004"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Basaran A. Pregnancy-induced hyperlipoproteinemia: review of the literature. Reprod Sci, 2009; 16: 431-437","DOI":"10.1177\/1933719108330569"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Ghio A, Bertolotto A, Resi V, Volpe L, Di Cianni G. Triglyceride metabolism in pregnancy. Adv Clin Chem, 2011; 55: 133-153","DOI":"10.1016\/B978-0-12-387042-1.00007-1"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Wong B, Ooi TC, Keely E. Severe gestational hypertriglyceridemia: A practical approach for clinicians. Obstet Med, 2015; 8: 158-167","DOI":"10.1177\/1753495X15594082"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, Retterst\u00f8l K. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis, 2006; 189: 451-457","DOI":"10.1016\/j.atherosclerosis.2006.01.002"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Warth MR, Arky RA, Knopp RH. Lipid metabolism in pregnancy. II. Altered lipid composition in intermediage, very low, low and high-density lipoprotein fractions. J Clin Endocrinol Metab, 1975; 41: 649-655","DOI":"10.1210\/jcem-41-4-649"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Potter JM, Nestel PJ. The hyperlipidemia of pregnancy in normal and complicated pregnancies. Am J Obstet Gynecol, 1979; 133: 165-170","DOI":"10.1016\/0002-9378(79)90469-1"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Salameh WA, Mastrogiannis DS. Maternal hyperlipidemia in pregnancy. Clin Obstet Gynecol, 1994; 37: 66-77","DOI":"10.1097\/00003081-199403000-00011"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Alvarez JJ, Montelongo A, Iglesias A, Lasunci\u00f3n MA, Herrera E. Longitudinal study on lipoprotein profile, high density lipoprotein subclass, and postheparin lipases during gestation in women. J Lipid Res, 1996; 37: 299-308","DOI":"10.1016\/S0022-2275(20)37617-3"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Herrera E. Lipid metabolism in pregnancy and its consequences in the fetus and newborn. Endocrine, 2002; 19: 43-55","DOI":"10.1385\/ENDO:19:1:43"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Papadakis EP, Sarigianni M, Mikhailidis DP, Mamopoulos A, Karagiannis V. Acute pancreatitis in pregnancy: an overview. Eur J Obstet Gynecol Reprod Biol, 2011; 159: 261-266","DOI":"10.1016\/j.ejogrb.2011.07.037"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Russi G. Severe dyslipidemia in pregnancy: The role of therapeutic apheresis. Transfus Apher Sci, 2015; 53: 283-287","DOI":"10.1016\/j.transci.2015.11.008"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Kekki M, Nikkil\u00e4 EA. Plasma triglyceride turnover during use of oral contraceptives. Metab Clin Exp, 1971; 20: 878-889","DOI":"10.1016\/0026-0495(71)90050-3"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB, Levy RI. The Effects of Estrogen Administration on Plasma Lipoprotein Metabolism in Premenopausal Females. The Journal of Clinical Endocrinology & Metabolism, 1983; 57: 262-267","DOI":"10.1210\/jcem-57-2-262"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Desoye G, Schweditsch MO, Pfeiffer KP, Zechner R, Kostner GM. Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. J Clin Endocrinol Metab, 1987; 64: 704-712","DOI":"10.1210\/jcem-64-4-704"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Lamon-Fava S, Diffenderfer MR, Barrett PHR, Wan WY, Postfai B, Nartsupha C, Dolnikowski GG, Schaefer EJ. Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women. Lipids, 2018; 53: 167-175","DOI":"10.1002\/lipd.12011"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Fredrickson DS, Lees RS. A SYSTEM FOR PHENOTYPING HYPERLIPOPROTEINEMIA. Circulation, 1965; 31: 321-327","DOI":"10.1161\/01.CIR.31.3.321"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Moulin P, Dufour R, Averna M, Arca M, Cefal\u00f9 AB, Noto D, D\u2019Erasmo L, Di Costanzo A, Mar\u00e7ais C, Alvarez-Sala Walther LA, Banach M, Bor\u00e9n J, Cramb R, Gouni-Berthold I, Hughes E, Johnson C, Pint\u00f3 X, Reiner \u017d, van Lennep JR, Soran H, Stefanutti C, Stroes E, Bruckert E. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an \u201cFCS score.\u201d Atherosclerosis, 2018; 275: 265-272","DOI":"10.1016\/j.atherosclerosis.2018.06.814"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Brown WV, Goldberg I, Duell B, Gaudet D. Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management. J Clin Lipidol, 2018; 12: 254-263","DOI":"10.1016\/j.jacl.2018.02.018"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Brown WV, Gaudet D, Goldberg I, Hegele R. Roundtable on etiology of familial chylomicronemia syndrome. J Clin Lipidol, 2018; 12: 5-11","DOI":"10.1016\/j.jacl.2017.12.015"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Dron JS, Wang J, Cao H, McIntyre AD, Iacocca MA, Menard JR, Movsesyan I, Malloy MJ, Pullinger CR, Kane JP, Hegele RA. Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol, 2019; 13: 80-88","DOI":"10.1016\/j.jacl.2018.10.006"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Toth PP, Grabner M, Ramey N, Higuchi K. Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels. Atherosclerosis, 2014; 237: 790-797","DOI":"10.1016\/j.atherosclerosis.2014.09.029"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Sekimoto M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Hirota M, Kimura Y, Takeda K, Isaji S, Koizumi M, Otsuki M, Matsuno S, JPN. JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobiliary Pancreat Surg, 2006; 13: 10-24","DOI":"10.1007\/s00534-005-1047-3"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Carr RA, Rejowski BJ, Cote GA, Pitt HA, Zyromski NJ. Systematic review of hypertriglyceridemia-induced acute pancreatitis: A more virulent etiology? Pancreatology, 2016; 16: 469-476","DOI":"10.1016\/j.pan.2016.02.011"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Rashid N, Sharma PP, Scott RD, Lin KJ, Toth PP. Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system. J Clin Lipidol, 2016; 10: 880-890","DOI":"10.1016\/j.jacl.2016.02.019"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Geng Y, Li W, Sun L, Tong Z, Li N, Li J. Severe acute pancreatitis during pregnancy: eleven years experience from a surgical intensive care unit. Dig Dis Sci, 2011; 56: 3672-3677","DOI":"10.1007\/s10620-011-1809-5"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Ramin KD, Ramin SM, Richey SD, Cunningham FG. Acute pancreatitis in pregnancy. Am J Obstet Gynecol, 1995; 173: 187-191","DOI":"10.1016\/0002-9378(95)90188-4"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and acute pancreatitis. JAMA Intern Med, 2013; 173: 162-164","DOI":"10.1001\/2013.jamainternmed.477"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. JAMA Intern Med, 2016; 176: 1834-1842","DOI":"10.1001\/jamainternmed.2016.6875"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol, 2014; 48: 195-203","DOI":"10.1097\/01.mcg.0000436438.60145.5a"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Authors\/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019; 290: 140-205","DOI":"10.1016\/j.atherosclerosis.2019.08.014"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Gaudet D, de Wal J, Tremblay K, D\u00e9ry S, van Deventer S, Freidig A, Brisson D, M\u00e9thot J. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl, 2010; 11: 55-60","DOI":"10.1016\/j.atherosclerosissup.2010.03.004"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Gaudet D, Blom D, Bruckert E, Stroes E, Kastelein J, John K, Malloy M, Moulin P, Retterst\u00f8\u013cl K, Hughes S, Tsimikas S, Witztum J. Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist. Journal of Clinical Lipidology, 2016; 10: 680-681","DOI":"10.1016\/j.jacl.2016.03.048"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Paquette M, Bernard S, Hegele RA, Baass A. Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis, 2019; 283: 137-142","DOI":"10.1016\/j.atherosclerosis.2018.12.019"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Zafrir B, Jubran A, Hijazi R, Shapira C. Clinical features and outcomes of severe, very severe, and extreme hypertriglyceridemia in a regional health service. Journal of Clinical Lipidology, 2018; 12: 928-936","DOI":"10.1016\/j.jacl.2018.03.086"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Fallat RW, Vester JW, Glueck CJ. Suppression of amylase activity by hypertriglyceridemia. JAMA, 1973; 225: 1331-1334","DOI":"10.1001\/jama.225.11.1331"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Melnick S, Nazir S, Gish D, Aryal MR. Hypertriglyceridemic pancreatitis associated with confounding laboratory abnormalities. J Community Hosp Intern Med Perspect, 2016; 6: 31808","DOI":"10.3402\/jchimp.v6.31808"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Singh A, Shrestha M, Anand C. Acute pancreatitis with normal amylase and lipase--an ED dilemma. Am J Emerg Med, 2016; 34: 940.e5-7","DOI":"10.1016\/j.ajem.2015.10.026"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Nayak KR, Daly RG. Images in clinical medicine. Eruptive xanthomas associated with hypertriglyceridemia and new-onset diabetes mellitus. N Engl J Med, 2004; 350: 1235","DOI":"10.1056\/NEJMicm030676"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Kumar J, Wierzbicki AS. Images in clinical medicine. Lipemia retinalis. N Engl J Med, 2005; 353: 823","DOI":"10.1056\/NEJMicm040437"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Stefanutti C, Labbadia G, Morozzi C. Severe hypertriglyceridemia-related acute pancreatitis. Ther Apher Dial, 2013; 17: 130-137","DOI":"10.1111\/1744-9987.12008"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Ahmad Z, Halter R, Stevenson M. Building a better understanding of the burden of disease in familial chylomicronemia syndrome. Expert Rev Clin Pharmacol, 2017; 10: 1-3","DOI":"10.1080\/17512433.2017.1251839"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Gelrud A, Williams KR, Hsieh A, Gwosdow AR, Gilstrap A, Brown A. The burden of familial chylomicronemia syndrome from the patients\u2019 perspective. Expert Rev Cardiovasc Ther, 2017; 15: 879-887","DOI":"10.1080\/14779072.2017.1372193"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Davidson M, Stevenson M, Hsieh A, Ahmad Z, Crowson C, Witztum JL. The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. Expert Rev Cardiovasc Ther, 2017; 15: 415-423","DOI":"10.1080\/14779072.2017.1311786"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Davidson M, Stevenson M, Hsieh A, Ahmad Z, Roeters van Lennep J, Crowson C, Witztum JL. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. J Clin Lipidol, 2018; 12: 898-907.e2","DOI":"10.1016\/j.jacl.2018.04.009"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics, 2011; 128 Suppl 5: S213-256","DOI":"10.1542\/peds.2009-2107C"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Buonuomo PS, Rabacchi C, Macchiaiolo M, Trenti C, Fasano T, Tarugi P, Bartuli A, Bertolini S, Calandra S. Incidental finding of severe hypertriglyceridemia in children. Role of multiple rare variants in genes affecting plasma triglyceride. Journal of Clinical Lipidology, 2017; 11: 1329-1337.e3","DOI":"10.1016\/j.jacl.2017.08.017"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110) Dominguez-Mu\u00f1oz JE, Malfertheiner P, Ditschuneit HH, Blanco-Chavez J, Uhl W, B\u00fcchler M, Ditschuneit H. Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. Int J Pancreatol, 1991; 10: 261-267","DOI":"10.1007\/BF02924164"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Watts GF, Morton K, Jackson P, Lewis B. Management of patients with severe hypertriglyceridaemia during pregnancy: report of two cases with familial lipoprotein lipase deficiency. Br J Obstet Gynaecol, 1992; 99: 163-166","DOI":"10.1111\/j.1471-0528.1992.tb14481.x"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Ma Y, Liu MS, Ginzinger D, Frohlich J, Brunzell JD, Hayden MR. Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172-->Cys mutation in the lipoprotein lipase gene. J Clin Invest, 1993; 91: 1953-1958","DOI":"10.1172\/JCI116414"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Glueck CJ, Streicher P, Wang P, Sprecher D, Falko JM. Treatment of severe familial hypertriglyceridemia during pregnancy with very-low-fat diet and n-3 fatty acids. Nutrition, 1996; 12: 202-205","DOI":"10.1016\/S0899-9007(97)85060-5"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Saravanan P, Blumenthal S, Anderson C, Stein R, Berkelhammer C. Plasma exchange for dramatic gestational hyperlipidemic pancreatitis. J Clin Gastroenterol, 1996; 22: 295-298","DOI":"10.1097\/00004836-199606000-00011"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) Suga S, Tamasawa N, Kinpara I, Murakami H, Kasai N, Onuma T, Ikeda Y, Takagi A, Suda T. Identification of homozygous lipoprotein lipase gene mutation in a woman with recurrent aggravation of hypertriglyceridaemia induced by pregnancy. J Intern Med, 1998; 243: 317-321","DOI":"10.1046\/j.1365-2796.1998.00306.x"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116) McGladdery SH, Frohlich JJ. Lipoprotein lipase and apoE polymorphisms: relationship to hypertriglyceridemia during pregnancy. J Lipid Res, 2001; 42: 1905-1912","DOI":"10.1016\/S0022-2275(20)31517-0"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117) Bartha I, Dinya T, Seres I, Paragh G, Ross C, Hayden MR, Bir\u00f3 S, Vargha G. Acute hypertriglyceridemic pancreatitis during pregnancy due to homozygous lipoprotein lipase gene mutation. Clin Chim Acta, 2009; 400: 137-138","DOI":"10.1016\/j.cca.2008.10.016"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118) Xie S-L, Chen T-Z, Huang X-L, Chen C, Jin R, Huang Z-M, Zhou M-T. Genetic Variants Associated with Gestational Hypertriglyceridemia and Pancreatitis. PLoS ONE, 2015; 10: e0129488","DOI":"10.1371\/journal.pone.0129488"},{"key":"119","unstructured":"119) G\u00fcrsoy A, Kulaksizoglu M, Sahin M, Ertugrul DT, Ozer F, Tutuncu NB, Demirag NG. Severe hypertriglyceridemia-induced pancreatitis during pregnancy. J Natl Med Assoc, 2006; 98: 655-657"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120) Goldberg AS, Hegele RA. Severe hypertriglyceridemia in pregnancy. J Clin Endocrinol Metab, 2012; 97: 2589-2596","DOI":"10.1210\/jc.2012-1250"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121) Gallos ID, Sivakumar K, Kilby MD, Coomarasamy A, Thangaratinam S, Vatish M. Pre-eclampsia is associated with, and preceded by, hypertriglyceridaemia: a meta-analysis. BJOG, 2013; 120: 1321-1332","DOI":"10.1111\/1471-0528.12375"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122) Al-Shali K, Wang J, Fellows F, Huff MW, Wolfe BM, Hegele RA. Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase. Clin Biochem, 2002; 35: 125-130","DOI":"10.1016\/S0009-9120(02)00283-7"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123) Stroes E, Moulin P, Parhofer KG, Rebours V, L\u00f6hr J-M, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl, 2017; 23: 1-7","DOI":"10.1016\/j.atherosclerosissup.2016.10.002"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124) Tremblay K, Gaudet D, Khoury E, Brisson D. Dissection of Clinical and Gene Expression Signatures of Familial versus Multifactorial Chylomicronemia. J Endocr Soc, 2020; 4: bvaa056","DOI":"10.1210\/jendso\/bvaa056"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125) Christian JB, Arondekar B, Buysman EK, Johnson SL, Seeger JD, Jacobson TA. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg\/dL in patients with severe hypertriglyceridemia. J Clin Lipidol, 2012; 6: 450-461","DOI":"10.1016\/j.jacl.2012.08.007"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126) Christian JB, Arondekar B, Buysman EK, Jacobson TA, Snipes RG, Horwitz RI. Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia. Am J Med, 2014; 127: 36-44.e1","DOI":"10.1016\/j.amjmed.2013.09.018"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127) Huffman KM, Hawk VH, Henes ST, Ocampo CI, Orenduff MC, Slentz CA, Johnson JL, Houmard JA, Samsa GP, Kraus WE, Bales CW. Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in Studies of a Targeted Risk Reduction Intervention through Defined Exercise I. Am Heart J, 2012; 164: 117-124","DOI":"10.1016\/j.ahj.2012.04.014"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128) Williams L, Wilson DP. Editorial commentary: Dietary management of familial chylomicronemia syndrome. J Clin Lipidol, 2016; 10: 462-465","DOI":"10.1016\/j.jacl.2015.12.023"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129) Williams L, Rhodes KS, Karmally W, Welstead LA, Alexander L, Sutton L, patients and families living with FCS. Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span. J Clin Lipidol, 2018; 12: 908-919","DOI":"10.1016\/j.jacl.2018.04.010"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130) Ewald N, Hardt PD, Kloer H-U. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol, 2009; 20: 497-504","DOI":"10.1097\/MOL.0b013e3283319a1d"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131) Brunzell JD, Hazzard WR, Porte D, Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest, 1973; 52: 1578-1585","DOI":"10.1172\/JCI107334"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132) DenBesten L, Reyna RH, Connor WE, Stegink LD. The different effects on the serum lipids and fecal steroids of high carbohydrate diets given orally or intravenously. J Clin Invest, 1973; 52: 1384-1393","DOI":"10.1172\/JCI107311"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133) Deng L-H, Xue P, Xia Q, Yang X-N, Wan M-H. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. World J Gastroenterol, 2008; 14: 4558-4561","DOI":"10.3748\/wjg.14.4558"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134) Nawaz H, Koutroumpakis E, Easler J, Slivka A, Whitcomb DC, Singh VP, Yadav D, Papachristou GI. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol, 2015; 110: 1497-1503","DOI":"10.1038\/ajg.2015.261"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135) Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol, 2009; 104: 984-991","DOI":"10.1038\/ajg.2009.27"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136) Kawashiri M, Higashikata T, Mizuno M, Takata M, Katsuda S, Miwa K, Nozue T, Nohara A, Inazu A, Kobayashi J, Koizumi J, Mabuchi H. Long-term course of lipoprotein lipase (LPL) deficiency due to homozygous LPL(Arita) in a patient with recurrent pancreatitis, retained glucose tolerance, and atherosclerosis. J Clin Endocrinol Metab, 2005; 90: 6541-6544","DOI":"10.1210\/jc.2005-1098"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137) Mikhail N, Trivedi K, Page C, Wali S, Cope D. Treatment of severe hypertriglyceridemia in nondiabetic patients with insulin. Am J Emerg Med, 2005; 23: 415-417","DOI":"10.1016\/j.ajem.2005.02.036"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138) Khan R, Jehangir W, Regeti K, Yousif A. Hypertriglyceridemia-Induced Pancreatitis: Choice of Treatment. Gastroenterology Res, 2015; 8: 234-236","DOI":"10.14740\/gr662e"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139) Inayat F, Zafar F, Baig AS, Chaudhry NA, Aslam A, Khan ZH, Iqbal MJ. Hypertriglyceridemic Pancreatitis Treated with Insulin Therapy: A Comparative Review of 34 Cases. Cureus, 2018; 10: e3501","DOI":"10.7759\/cureus.3501"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140) Weintraub M, Rassin T, Eisenberg S, Ringel Y, Grosskopf I, Iaina A, Charach G, Liron M, Rubinstein A. Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation. J Lipid Res, 1994; 35: 229-238","DOI":"10.1016\/S0022-2275(20)41211-8"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141) Schuff-Werner P, Fenger S, Kohlschein P. Role of lipid apheresis in changing times. Clin Res Cardiol Suppl, 2012; 7: 7-14","DOI":"10.1007\/s11789-012-0049-3"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142) Stefanutti C, Julius U. Treatment of primary hypertriglyceridemia states--General approach and the role of extracorporeal methods. Atheroscler Suppl, 2015; 18: 85-94","DOI":"10.1016\/j.atherosclerosissup.2015.02.017"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143) He W-H, Yu M, Zhu Y, Xia L, Liu P, Zeng H, Zhu Y, Lv N-H. Emergent Triglyceride-lowering Therapy With Early High-volume Hemofiltration Against Low-Molecular-Weight Heparin Combined With Insulin in Hypertriglyceridemic Pancreatitis: A Prospective Randomized Controlled Trial. J Clin Gastroenterol, 2016; 50: 772-778","DOI":"10.1097\/MCG.0000000000000552"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144) Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, Szczepiorkowski ZM, Williams ME, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher, 2013; 28: 145-284","DOI":"10.1002\/jca.21276"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145) Thompson GR. Lipoprotein apheresis. Curr Opin Lipidol, 2010; 21: 487-491","DOI":"10.1097\/MOL.0b013e32833e13fd"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146) Ewald N, Kloer H-U. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis. Clin Res Cardiol Suppl, 2012; 7: 31-35","DOI":"10.1007\/s11789-012-0042-x"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147) Basar R, Uzum AK, Canbaz B, Dogansen SC, Kalayoglu-Besisik S, Altay-Dadin S, Aral F, Ozbey NC. Therapeutic apheresis for severe hypertriglyceridemia in pregnancy. Arch Gynecol Obstet, 2013; 287: 839-843","DOI":"10.1007\/s00404-013-2786-z"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148) Safi F, Toumeh A, Abuissa Qadan MA, Karaz R, AlAkdar B, Assaly R. Management of familial hypertriglyceridemia-induced pancreatitis during pregnancy with therapeutic plasma exchange: a case report and review of literature. Am J Ther, 2014; 21: e134-136","DOI":"10.1097\/MJT.0b013e31825b9e98"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149) Gupta N, Ahmed S, Shaffer L, Cavens P, Blankstein J. Severe hypertriglyceridemia induced pancreatitis in pregnancy. Case Rep Obstet Gynecol, 2014; 2014: 485493","DOI":"10.1155\/2014\/485493"},{"key":"150","doi-asserted-by":"crossref","unstructured":"150) Newman CB, Blaha MJ, Boord JB, Cariou B, Chait A, Fein HG, Ginsberg HN, Goldberg IJ, Murad MH, Subramanian S, Tannock LR. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 2020; 105: 3613-3682","DOI":"10.1210\/clinem\/dgaa674"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151) Piolot A, Nadler F, Cavallero E, Coquard JL, Jacotot B. Prevention of recurrent acute pancreatitis in patients with severe hypertriglyceridemia: value of regular plasmapheresis. Pancreas, 1996; 13: 96-99","DOI":"10.1097\/00006676-199607000-00013"},{"key":"152","unstructured":"152) Hovland A, Hardersen R, Mollnes TE, Lappeg\u00e5rd KT. Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia. JOP, 2010; 11: 467-469"},{"key":"153","doi-asserted-by":"crossref","unstructured":"153) Schaap-Fogler M, Schurr D, Schaap T, Leitersdorf E, Rund D. Long-term plasma exchange for severe refractory hypertriglyceridemia: a decade of experience demonstrates safety and efficacy. J Clin Apher, 2009; 24: 254-258","DOI":"10.1002\/jca.20224"},{"key":"154","doi-asserted-by":"crossref","unstructured":"154) Saleh MA, Mansoor E, Cooper GS. Case of familial hyperlipoproteinemia type III hypertriglyceridemia induced acute pancreatitis: Role for outpatient apheresis maintenance therapy. World J Gastroenterol, 2017; 23: 7332-7336","DOI":"10.3748\/wjg.v23.i40.7332"},{"key":"155","doi-asserted-by":"crossref","unstructured":"155) Niro J, Sapin V, Constantin J-M, Cotte B, Lebel A, Roszyk L, R Eglizot null, Tauveron I, Jacquetin B, L\u00e9mery D, Gallot D. [Management of gestational hypertriglyceridemia by plasmapheresis]. Gynecol Obstet Fertil, 2007; 35: 1133-1135","DOI":"10.1016\/j.gyobfe.2007.08.024"},{"key":"156","doi-asserted-by":"crossref","unstructured":"156) Sivakumaran P, Tabak SW, Gregory K, Pepkowitz SH, Klapper EB. Management of familial hypertriglyceridemia during pregnancy with plasma exchange. J Clin Apher, 2009; 24: 42-46","DOI":"10.1002\/jca.20192"},{"key":"157","doi-asserted-by":"crossref","unstructured":"157) Mizushima T, Ochi K, Matsumura N, Ichimura M, Ishibashi T, Tsuboi K, Harada H. Prevention of hyperlipidemic acute pancreatitis during pregnancy with medium-chain triglyceride nutritional support. Int J Pancreatol, 1998; 23: 187-192","DOI":"10.1007\/BF02788396"},{"key":"158","doi-asserted-by":"crossref","unstructured":"158) Athyros VG, Giouleme OI, Nikolaidis NL, Vasiliadis TV, Bouloukos VI, Kontopoulos AG, Eugenidis NP. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol, 2002; 34: 472-475","DOI":"10.1097\/00004836-200204000-00020"},{"key":"159","doi-asserted-by":"crossref","unstructured":"159) Tsai EC, Brown JA, Veldee MY, Anderson GJ, Chait A, Brunzell JD. Potential of essential fatty acid deficiency with extremely low fat diet in lipoprotein lipase deficiency during pregnancy: A case report. BMC Pregnancy Childbirth, 2004; 4: 27","DOI":"10.1186\/1471-2393-4-27"},{"key":"160","unstructured":"160) Greenberg JA, Bell SJ, Ausdal WV. Omega-3 Fatty Acid supplementation during pregnancy. Rev Obstet Gynecol, 2008; 1: 162-169"},{"key":"161","doi-asserted-by":"crossref","unstructured":"161) Nelson-Piercy C, Crook MA. Severe hypertriglyceridemia complicating pregnancy, management by dietary intervention and omega-3 fatty acid supplementation. Nutrition, 2009; 25: 1098-1099","DOI":"10.1016\/j.nut.2009.05.002"},{"key":"162","doi-asserted-by":"crossref","unstructured":"162) Takaishi K, Miyoshi J, Matsumura T, Honda R, Ohba T, Katabuchi H. Hypertriglyceridemic acute pancreatitis during pregnancy: prevention with diet therapy and omega-3 fatty acids in the following pregnancy. Nutrition, 2009; 25: 1094-1097","DOI":"10.1016\/j.nut.2009.04.009"},{"key":"163","doi-asserted-by":"crossref","unstructured":"163) Saadi HF, Kurlander DJ, Erkins JM, Hoogwerf BJ. Severe hypertriglyceridemia and acute pancreatitis during pregnancy: treatment with gemfibrozil. Endocr Pract, 1999; 5: 33-36","DOI":"10.4158\/EP.5.1.33"},{"key":"164","doi-asserted-by":"crossref","unstructured":"164) Abu Musa AA, Usta IM, Rechdan JB, Nassar AH. Recurrent hypertriglyceridemia-induced pancreatitis in pregnancy: a management dilemma. Pancreas, 2006; 32: 227-228","DOI":"10.1097\/01.mpa.0000202943.70708.2d"},{"key":"165","doi-asserted-by":"crossref","unstructured":"165) Hill AJ, Pacheco LD, Saade G, Hankins GDV. Familial hypertriglyceridemia in pregnancy. Int J Gynaecol Obstet, 2014; 125: 80-81","DOI":"10.1016\/j.ijgo.2013.11.004"},{"key":"166","doi-asserted-by":"crossref","unstructured":"166) Lim R, Rodger SJ, Hawkins TL-A. Presentation and management of acute hypertriglyceridemic pancreatitis in pregnancy: A case report. Obstet Med, 2015; 8: 200-203","DOI":"10.1177\/1753495X15605697"},{"key":"167","doi-asserted-by":"crossref","unstructured":"167) Hegele RA, Tsimikas S. Lipid-Lowering Agents. Circ Res, 2019; 124: 386-404","DOI":"10.1161\/CIRCRESAHA.118.313171"},{"key":"168","doi-asserted-by":"crossref","unstructured":"168) Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AME, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ, Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, 2013; 381: 40-46","DOI":"10.1016\/S0140-6736(12)61731-0"},{"key":"169","doi-asserted-by":"crossref","unstructured":"169) Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years\u2019 treatment with lomitapide. JAMA Intern Med, 2014; 174: 443-447","DOI":"10.1001\/jamainternmed.2013.13309"},{"key":"170","doi-asserted-by":"crossref","unstructured":"170) Blom DJ, Averna MR, Meagher EA, du Toit Theron H, Sirtori CR, Hegele RA, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Larrey D, Bloedon LT, Foulds P, Rader DJ, Cuchel M. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation, 2017; 136: 332-335","DOI":"10.1161\/CIRCULATIONAHA.117.028208"},{"key":"171","doi-asserted-by":"crossref","unstructured":"171) Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, 2010; 375: 998-1006","DOI":"10.1016\/S0140-6736(10)60284-X"},{"key":"172","doi-asserted-by":"crossref","unstructured":"172) Panta R, Dahal K, Kunwar S. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials. J Clin Lipidol, 2015; 9: 217-225","DOI":"10.1016\/j.jacl.2014.12.006"},{"key":"173","doi-asserted-by":"crossref","unstructured":"173) Gryn SE, Hegele RA. Novel therapeutics in hypertriglyceridemia. Curr Opin Lipidol, 2015; 26: 484-491","DOI":"10.1097\/MOL.0000000000000231"},{"key":"174","doi-asserted-by":"crossref","unstructured":"174) Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, O\u2019Dea L, Bruckert E. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med, 2019; 381: 531-542","DOI":"10.1056\/NEJMoa1715944"},{"key":"175","doi-asserted-by":"crossref","unstructured":"175) Denison H, Nilsson C, L\u00f6fgren L, Himmelmann A, M\u00e5rtensson G, Knutsson M, Al-Shurbaji A, Tornqvist H, Eriksson JW. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab, 2014; 16: 334-343","DOI":"10.1111\/dom.12221"},{"key":"176","doi-asserted-by":"crossref","unstructured":"176) Meyers CD, Tremblay K, Amer A, Chen J, Jiang L, Gaudet D. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis, 2015; 14: 8","DOI":"10.1186\/s12944-015-0006-5"},{"key":"177","doi-asserted-by":"crossref","unstructured":"177) Meyers CD, Amer A, Majumdar T, Chen J. Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects. J Clin Pharmacol, 2015; 55: 1031-1041","DOI":"10.1002\/jcph.509"},{"key":"178","doi-asserted-by":"crossref","unstructured":"178) Graham MJ, Lee RG, Brandt TA, Tai L-J, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med, 2017; 377: 222-232","DOI":"10.1056\/NEJMoa1701329"},{"key":"179","doi-asserted-by":"crossref","unstructured":"179) Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH, Lee I-T, Liang K-W, Guo X, Rotter JI, Chen Y-DI, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybj\u00e6rg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med, 2017; 377: 211-221","DOI":"10.1056\/NEJMoa1612790"},{"key":"180","doi-asserted-by":"crossref","unstructured":"180) Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, Chyu K-Y, Sasiela WJ, Chan K-C, Brisson D, Khoury E, Banerjee P, Gusarova V, Gromada J, Stahl N, Yancopoulos GD, Hovingh GK. ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. N Engl J Med, 2017; 377: 296-297","DOI":"10.1056\/NEJMc1705994"},{"key":"181","doi-asserted-by":"crossref","unstructured":"181) Ahmad Z, Banerjee P, Hamon S, Chan K-C, Bouzelmat A, Sasiela WJ, Pordy R, Mellis S, Dansky H, Gipe DA, Dunbar RL. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. Circulation, 2019; 140: 470-486","DOI":"10.1161\/CIRCULATIONAHA.118.039107"},{"key":"182","doi-asserted-by":"crossref","unstructured":"182) Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan K-C, Gipe DA, Khilla N, Pordy R, Weinreich DM, Yancopoulos GD, Zhang Y, Gaudet D, ELIPSE HoFH Investigators. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med, 2020; 383: 711-720","DOI":"10.1056\/NEJMoa2004215"},{"key":"183","doi-asserted-by":"crossref","unstructured":"183) Haas JT, Winter HS, Lim E, Kirby A, Blumenstiel B, DeFelice M, Gabriel S, Jalas C, Branski D, Grueter CA, Toporovski MS, Walther TC, Daly MJ, Farese RV. DGAT1 mutation is linked to a congenital diarrheal disorder. J Clin Invest, 2012; 122: 4680-4684","DOI":"10.1172\/JCI64873"},{"key":"184","doi-asserted-by":"crossref","unstructured":"184) Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET, Elisaf MS. The effects of ezetimibe and\/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids, 2010; 45: 445-450","DOI":"10.1007\/s11745-010-3409-0"},{"key":"185","doi-asserted-by":"crossref","unstructured":"185) Blackett P, Tryggestad J, Krishnan S, Li S, Xu W, Alaupovic P, Quiroga C, Copeland K. Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat. J Clin Lipidol, 2013; 7: 132-139","DOI":"10.1016\/j.jacl.2012.11.006"},{"key":"186","doi-asserted-by":"crossref","unstructured":"186) Gaudet D, M\u00e9thot J, D\u00e9ry S, Brisson D, Essiembre C, Tremblay G, Tremblay K, de Wal J, Twisk J, van den Bulk N, Sier-Ferreira V, van Deventer S. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther, 2013; 20: 361-369","DOI":"10.1038\/gt.2012.43"},{"key":"187","doi-asserted-by":"crossref","unstructured":"187) Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med, 1998; 339: 653-658","DOI":"10.1056\/NEJM199809033391002"},{"key":"188","doi-asserted-by":"crossref","unstructured":"188) Schneider A, Barmada MM, Slivka A, Martin JA, Whitcomb DC. Clinical characterization of patients with idiopathic chronic pancreatitis and SPINK1 Mutations. Scand J Gastroenterol, 2004; 39: 903-904","DOI":"10.1080\/00365520410006710"},{"key":"189","doi-asserted-by":"crossref","unstructured":"189) Chen J-M, F\u00e9rec C. Chronic pancreatitis: genetics and pathogenesis. Annu Rev Genomics Hum Genet, 2009; 10: 63-87","DOI":"10.1146\/annurev-genom-082908-150009"},{"key":"190","doi-asserted-by":"crossref","unstructured":"190) Whitcomb DC. Genetic aspects of pancreatitis. Annu Rev Med, 2010; 61: 413-424","DOI":"10.1146\/annurev.med.041608.121416"},{"key":"191","doi-asserted-by":"crossref","unstructured":"191) Tremblay K, Dubois-Bouchard C, Brisson D, Gaudet D. Association of CTRC and SPINK1 gene variants with recurrent hospitalizations for pancreatitis or acute abdominal pain in lipoprotein lipase deficiency. Front Genet, 2014; 5: 90","DOI":"10.3389\/fgene.2014.00090"},{"key":"192","doi-asserted-by":"crossref","unstructured":"192) Benlian P, De Gennes JL, Foubert L, Zhang H, Gagn\u00e9 SE, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med, 1996; 335: 848-854","DOI":"10.1056\/NEJM199609193351203"},{"key":"193","doi-asserted-by":"crossref","unstructured":"193) Ebara T, Okubo M, Horinishi A, Adachi M, Murase T, Hirano T. No evidence of accelerated atherosclerosis in a 66-yr-old chylomicronemia patient homozygous for the nonsense mutation (Tyr61-->stop) in the lipoprotein lipase gene. Atherosclerosis, 2001; 159: 375-379","DOI":"10.1016\/S0021-9150(01)00510-X"},{"key":"194","doi-asserted-by":"crossref","unstructured":"194) Maki KC, Guyton JR, Orringer CE, Hamilton-Craig I, Alexander DD, Davidson MH. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. J Clin Lipidol, 2016; 10: 905-914","DOI":"10.1016\/j.jacl.2016.03.008"},{"key":"195","doi-asserted-by":"crossref","unstructured":"195) Shah NP, Cho L, Ahmed HM. Familial Chylomicronemia Syndrome: Clinical Characteristics and Long-Term Cardiovascular Outcomes. J Am Coll Cardiol, 2018; 72: 1177-1179","DOI":"10.1016\/j.jacc.2018.06.042"},{"key":"196","doi-asserted-by":"crossref","unstructured":"196) Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM, REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med, 2019; 380: 11-22","DOI":"10.1056\/NEJMoa1812792"},{"key":"197","doi-asserted-by":"crossref","unstructured":"197) Musunuru K, Kathiresan S. Genetics of Common, Complex Coronary Artery Disease. Cell, 2019; 177: 132-145","DOI":"10.1016\/j.cell.2019.02.015"},{"key":"198","doi-asserted-by":"crossref","unstructured":"198) Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet, 2010; 375: 1634-1639","DOI":"10.1016\/S0140-6736(10)60545-4"},{"key":"199","doi-asserted-by":"crossref","unstructured":"199) Do R, Stitziel NO, Won H-H, J\u00f8rgensen AB, Duga S, Angelica Merlini P, Kiezun A, Farrall M, Goel A, Zuk O, Guella I, Asselta R, Lange LA, Peloso GM, Auer PL, NHLBI Exome Sequencing Project, Girelli D, Martinelli N, Farlow DN, DePristo MA, Roberts R, Stewart AFR, Saleheen D, Danesh J, Epstein SE, Sivapalaratnam S, Hovingh GK, Kastelein JJ, Samani NJ, Schunkert H, Erdmann J, Shah SH, Kraus WE, Davies R, Nikpay M, Johansen CT, Wang J, Hegele RA, Hechter E, Marz W, Kleber ME, Huang J, Johnson AD, Li M, Burke GL, Gross M, Liu Y, Assimes TL, Heiss G, Lange EM, Folsom AR, Taylor HA, Olivieri O, Hamsten A, Clarke R, Reilly DF, Yin W, Rivas MA, Donnelly P, Rossouw JE, Psaty BM, Herrington DM, Wilson JG, Rich SS, Bamshad MJ, Tracy RP, Cupples LA, Rader DJ, Reilly MP, Spertus JA, Cresci S, Hartiala J, Tang WHW, Hazen SL, Allayee H, Reiner AP, Carlson CS, Kooperberg C, Jackson RD, Boerwinkle E, Lander ES, Schwartz SM, Siscovick DS, McPherson R, Tybjaerg-Hansen A, Abecasis GR, Watkins H, Nickerson DA, Ardissino D, Sunyaev SR, O\u2019Donnell CJ, Altshuler D, Gabriel S, Kathiresan S. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature, 2015; 518: 102-106","DOI":"10.1038\/nature13917"},{"key":"200","doi-asserted-by":"crossref","unstructured":"200) Tremblay K, M\u00e9thot J, Brisson D, Gaudet D. Etiology and risk of lactescent plasma and severe hypertriglyceridemia. J Clin Lipidol, 2011; 5: 37-44","DOI":"10.1016\/j.jacl.2010.11.004"},{"key":"201","doi-asserted-by":"crossref","unstructured":"201) Fu J, Kwok S, Sinai L, Abdel-Razek O, Babula J, Chen D, Farago E, Fernandopulle N, Leith S, Loyzer M, Lu C, Malkani N, Morris N, Schmidt M, Stringer R, Whitehead H, Ban MR, Dub\u00e9 JB, McIntyre A, Johansen CT, Cao H, Wang J, Hegele RA. Western Database of Lipid Variants (WDLV): a catalogue of genetic variants in monogenic dyslipidemias. Can J Cardiol, 2013; 29: 934-939","DOI":"10.1016\/j.cjca.2013.01.008"},{"key":"202","doi-asserted-by":"crossref","unstructured":"202) Berberich AJ, Hegele RA. The role of genetic testing in dyslipidaemia. Pathology, 2019; 51: 184-192","DOI":"10.1016\/j.pathol.2018.10.014"},{"key":"203","doi-asserted-by":"crossref","unstructured":"203) Ng DM, Burnett JR, Bell DA, Hegele RA, Hooper AJ. Update on the diagnosis, treatment and management of rare genetic lipid disorders. Pathology, 2019; 51: 193-201","DOI":"10.1016\/j.pathol.2018.11.005"},{"key":"204","doi-asserted-by":"crossref","unstructured":"204) Garg A, Garg V, Hegele RA, Lewis GF. Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice. Lancet Diabetes Endocrinol, 2019; 7: 880-886","DOI":"10.1016\/S2213-8587(19)30156-1"},{"key":"205","doi-asserted-by":"crossref","unstructured":"205) Steinhagen-Thiessen E, Stroes E, Soran H, Johnson C, Moulin P, Iotti G, Zibellini M, Ossenkoppele B, Dippel M, Averna MR, GENIALL Investigators. The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency. Atherosclerosis, 2017; 262: 146-153","DOI":"10.1016\/j.atherosclerosis.2016.08.023"},{"key":"206","doi-asserted-by":"crossref","unstructured":"206) Ng DM, Hooper AJ, Bellgard MI, Burnett JR. The role of patient registries for rare genetic lipid disorders. Curr Opin Lipidol, 2018; 29: 156-162","DOI":"10.1097\/MOL.0000000000000485"},{"key":"207","doi-asserted-by":"crossref","unstructured":"207) Huang C-Q, Dong B-R, Wu H-M, Zhang Y-L, Wu J-H, Lu Z-C, Flaherty JH. Association of cognitive impairment with serum lipid\/lipoprotein among Chinese nonagenarians and centenarians. Dement Geriatr Cogn Disord, 2009; 27: 111-116","DOI":"10.1159\/000194660"},{"key":"208","doi-asserted-by":"crossref","unstructured":"208) Morley JE, Banks WA. Lipids and cognition. J Alzheimers Dis, 2010; 20: 737-747","DOI":"10.3233\/JAD-2010-091576"},{"key":"209","doi-asserted-by":"crossref","unstructured":"209) Hauenschild A, Ewald N, Schnell-Kretschmer H, Porsch-Oezcueruemez M, Kloer H-U, Hardt PD. Successful long-term treatment of severe hypertriglyceridemia by feedback control with lipid self-monitoring. Ann Nutr Metab, 2008; 52: 215-220","DOI":"10.1159\/000138126"},{"key":"210","doi-asserted-by":"crossref","unstructured":"210) Lookene A, Zhang L, Hultin M, Olivecrona G. Rapid subunit exchange in dimeric lipoprotein lipase and properties of the inactive monomer. J Biol Chem, 2004; 279: 49964-49972","DOI":"10.1074\/jbc.M407419200"},{"key":"211","doi-asserted-by":"crossref","unstructured":"211) Beigneux AP, Allan CM, Sandoval NP, Cho GW, Heizer PJ, Jung RS, Stanhope KL, Havel PJ, Birrane G, Meiyappan M, Gill JE, Murakami M, Miyashita K, Nakajima K, Ploug M, Fong LG, Young SG. Lipoprotein lipase is active as a monomer. Proc Natl Acad Sci USA, 2019; 116: 6319-6328","DOI":"10.1073\/pnas.1900983116"},{"key":"212","doi-asserted-by":"crossref","unstructured":"212) Gunn KH, Roberts BS, Wang F, Strauss JD, Borgnia MJ, Egelman EH, Neher SB. The structure of helical lipoprotein lipase reveals an unexpected twist in lipase storage. Proc Natl Acad Sci USA, 2020; 117: 10254-10264","DOI":"10.1073\/pnas.1916555117"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/28\/9\/28_RV17054\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T04:16:23Z","timestamp":1630728983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/28\/9\/28_RV17054\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":212,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv17054","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"article-number":"RV17054"}}